Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
MK-3475 vs. paclitaxel, Docetaxel or vinflunine in metastatic urothelial cancer
-Evaluate PFS per RECIST 1.1 by blinded independent radiologists’ review of all subjects with recurrent/progressive metastatic urothelial cancer treated with pembrolizumab (MK-3475) compared to paclit...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Phase IIa Open Label, Randomized Clinical Trial to Study Vintafolide and Paclitaxel in Subjects with Advanced Triple Negative Breast Cancer Using SPECT/CT scan with Etarfolatide (EC20) for Subject Selection Ensayo clínico de fase IIa abierto y aleatorizado para estudiar Vintafolide y paclitaxel en pacientes con cáncer de mama triplemente negativo avanzado, con selección de pacientes mediante etarfolatide (EC20)
To evaluate the progression-free survival of vintafolide monotherapy relative to paclitaxel and the progression-free survival of vintafolide + paclitaxel combination therapy relative to paclitaxel in...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A Phase III, Randomized, Double-blind Study to Evaluate Chemotherapy plus Pembrolizumab vs Chemotherapy plus Placebo as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
1. To evaluate the rate of pCR using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) as assessed by the local pathologist at the ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A clinical research study to test the safety/tolerability and effectiveness of an investigational study medication (subcutaneous SCH 900222/MK-3222) in improving the signs and symptoms of moderate-to-severe chronic plaque psoriasis, and to compare it to an approved medication for the treatment of psoriasis called etanercept
Primary Efficacy Objective: To assess the efficacy of SCH 900222/MK-3222, hereafter referred to as MK-3222, compared to placebo in the treatment of moderate-to-severe chronic plaque psoriasis as measu...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Oral MK8669 in Children/Adolescents with Solid Tumors (6-17 years)
• To identify the dose limiting toxicities (DLT) and maximum tolerated dose (MTD) of ridaforolimus when administered to children from 6 to less than 18 years of age with advanced solid tumours. • To...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A Study of Boceprevir in Patients who have HIV and Hepatitis C
The primary objective of this study is to compare the efficacy of boceprevir (PO) in combination with peginterferon alfa-2b (PEG2b) (SC) plus ribavirin weight-based dosing (WBD) PO to therapy with PEG...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Extended-Release (ER) Niacin and Laropiprant (ERN/LRPT) in Patients with Dyslipidemia
Main objective: Assess the effects of ERN/LRPT relative to ERN on flushing during the post-withdrawal dosing period as measured by number of days/week with GFSS >4 during weeks 21 to 32.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
sitagliptin +simvastatin coadministration safety study sitagliptin és simvastatin egyidejű alkalmazásának biztonságossági vizsgálata
1. To assess the effect of MK-0431D compared to sitagliptin alone on A1C. 2. To assess the safety and tolerability of MK-0431D.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Phase III study of carboplatin and paclitaxel or nano particle albumin-bound paclitaxel (nab-paclitaxel) with or without pembrolizumab in first line metastatic squamous NSCLC. Estudio de fase III de carboplatino y paclitaxel o paclitaxel unido a albúmina en nanopartículas (nab-paclitaxel), con o sin pembrolizumab, en el CPNM epidermoide y metastásico en primera línea de tratamiento
In subjects with metastatic squamous non-small cell lung cancer (NSCLC) receiving investigator’s choice of standard of care chemotherapy (i.e. carboplatin and a taxane): 1. To evaluate progression fre...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
IMI/REL (MK-7655A) vs. CMS + IMI in Subjects with Imipenem-Resistant Bacterial Infection
(1) To estimate the proportion of subjects with favorable overall response to IMI/MK-7655 (Treatment Group 1 only) and to CMS + IMI (Treatment Group 2). The overall response will be estimated based o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant